| Autor: |
Rosing, H., Lustig, V., Van Warmerdam, L. J. C., Huizing, M. T., Bokkel Huinink, W. W. Ten, Schellens, J. H. M., Rodenhuis, S., Bult, A., Beijnen, J. H., van Warmerdam, L J, ten Bokkel Huinink, W W, Schellens, J H |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Mar2000, Vol. 45 Issue 3, p213-218, 6p |
| Abstrakt: |
Docetaxel, a taxane antitumor agent, was administered to 24 patients by a 1-h intravenous infusion at a dose level of 100 mg/m(2) with pharmacokinetic monitoring. The plasma concentration-versus-time data were fitted with a three-compartment model. The mean area under the curve (AUC) for docetaxel was 3.1 +/- 0.9 h. mg/l and the clearance was 34.8 +/- 9.3 l/h per m(2). There was considerable interpatient pharmacokinetic variability. In 33% of the patient population, metabolites were detected in plasma samples collected 5-30 min after the end of the infusion. The cyclized oxazolidinedione metabolite M4 was most frequently present and was detected in 8 out of 24 patients with maximal concentrations between 0.022 and 0.23 mg/l. Logistic regression analysis was performed to predict M4 docetaxel metabolism. In the final model, alanine aminotransferase and alkaline phosphatase levels were the strongest predictors. No relationship was found between M4 metabolism and percentage decrease in neutrophil count in this study. Three patients with high M4 concentrations in plasma during course 1 suffered from most pronounced fluid retention (grade 2-3) after two to five courses. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink